



IFW

PATENT
ATTORNEY DOCKET NO. 04843/112002

Certificate of Mailing: Date of Deposit: May 2, 2007

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Megan Kiley
Printed name of person mailing correspondence

Megan Kiley
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Yurgelun-Todd et al.

Confirmation No.: 5991

Serial No.: 10/556,134

Art Unit: Not Yet Assigned

Filed: November 9, 2005

Examiner: Not Yet Assigned

Customer No.: 21559

Title: USE OF SECRETIN IN TREATMENTS OF DISORDERS ASSOCIATED
WITH THE AMYGDALA

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450



INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed, with the exception of U.S. patents and U.S. patent application publications.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

This statement is being filed before the receipt of a first Office action on the merits.

If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,
Date: May 2, 2007  
Karen L. Elbing, Ph.D.
Reg. No. 35,238

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045

J. Cooper McDonald, Ph.D.
Reg. No. 52,011

Sheet 1 of 3

SUBSTITUTE FORM PTO-1449 (MODIFIED) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	04843/112002
		Serial No.	10/556,134
		Applicant	YURGELUN-TODD
		Filing Date	November 9, 2005
		Group	Not Yet Assigned
		IDS Filed	May 2, 2007

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
	US2003/00962 64 A1	5/22/03	Altar et al.			
	5,585,118	12/17/96	Stoll			
	6,020,310	2/1/00	Beck et al.			
	6,020,314	2/1/00	McMichael			
	6,117,890	9/12/00	Bymaster et al.			
	6,197,746 B1	3/6/01	Beck et al.			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	WO01/32196	5/10/01	WIPO			
	WO01/37801	5/31/01	WIPO			
	WO03/042654 A2	5/22/03	WIPO			
	WO03/92716	11/13/03	WIPO			

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Adolphs et al. "The Human Amygdala in Social Judgement" <i>Nature</i> 393:470-474. (1998)
	Adolphs et al. "Abnormal Processing of Social Information from Faces in Autism" <i>J. Cog. Neurosci.</i> 13:232-240. (2001)
	Adolphs et al. "Impaired Recognition of Emotion in Facial Expressions Following Bilateral Damage to the Human Amygdala" <i>Nature</i> 372:669-672. (1994)
	Adolphs et al. "Fear and the Human Amygdala" <i>J. Neurosci.</i> 15:5879-5891. (1995)
	Baird et al. "Functional Magnetic Resonance Imaging of Facial Affect Recognition in Children and Adolescents" <i>J. Am. Acad. Child. Adolesc. Psychiatry</i> 38:195-199. (1999)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	04843/112002
		Serial No.	10/556,134
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant	YURGELUN-TODD
		Filing Date	November 9, 2005
		Group	Not Yet Assigned
		IDS Filed	May 2, 2007
(37 C.F.R. § 1.98(b))			

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Baron-Cohen et al. "The Amygdala Theory of Autism" <i>Neurosci. Biobehav. Rev.</i> 24:355-364. (2000)
	Baron-Cohen et al. "Social Intelligence in the Normal and Autistic Brain: An fMRI Study" <i>Eur. J. Neurosci.</i> 11:1891-1898. (1999)
	Breiter and Rauch "Functional MRI and the Study of OCD: From Symptom Provocation to Cognitive-Behavioral Probes of Cortico-Striatal Systems and the Amygdala" <i>Neuroimage</i> 4:S127-S138. (1996)
	Coniglio et al. "A Randomized, Double-Blind Placebo-Controlled Trial of Single-Dose Intravenous Secretin as Treatment For Children With Autism" <i>J. Pediatr.</i> 138:649-655. (2001)
	Davis. "Neurobiology of Fear Responses: the Role of the Amygdala" <i>J. Neuropsychiatry Clin. Neurosci.</i> 9:382-402. (1997)
	Emery and Amaral. "The Role of the Amygdala in Primate Social Cognition" Chapter 8 In: <i>Cognitive Neuroscience of Emotion</i> (Lane RD, Nadel L, eds), pp 156-191. New York. (2000)
	Goulet et al. "A Secretin I.V. Infusion Activates Gene Expression in the Central Amygdala of Rats" <i>Neuroscience</i> 118:881-888. (2003)
	Hariri et al. "Dextroamphetamine Modulates the Response of the Human Amygdala" <i>Neuropsychopharmacology</i> 27:1036-1040. (2002)
	Hariri. "Modulating Emotional Responses: Effects of a Neocortical Network On the Limbic System" <i>NeuroReport</i> 11:43-48. (2000)
	Herlihy et al., "Age and Number of Doses are Determinants of the Response to Secretin in Young Children with Autism" <i>International Meeting for Autism Research (IMFAR)</i> . Orlando, FL. (2002)
	Horvath et al. "Improved Social and Language Skills After Secretin Administration in Patients with Autistic Spectrum Disorders" <i>J. Assoc. Acad. Minor. Phys.</i> 9:9-15. (1998)
	Howard et al. "Convergent Neuroanatomical and Behavioural Evidence of an Amygdala Hypothesis of Autism" <i>NeuroReport</i> 11:2931-2935. (2000)
	Kalin et al. "Functional Magnetic Resonance Imaging Studies of Emotional Processing in Normal and Depressed Patients: Effects of Venlafaxine" <i>J. Clin. Psychiatry</i> 58:32-39. (1997)
	Kosaka et al. "Differential Amygdala Response During Facial Recognition in Patients With Schizophrenia: An fMRI Study" <i>Schizophr. Res.</i> 57:87-95. (2002)
	LeDoux. "Emotional Networks and Motor Control: A Fearful View" <i>In Prog. Brain Res.</i> 107:437-446. (1996)
	McGaugh et al. "Amygdala Role in Modulation of Memory Storage" <i>In The Amygdala: A Functional Analysis</i> , J.P. Aggleton, ed. London: Oxford University Press 391-423 (2000)
	Morelli et al. "Induction of Fos-Like-Immunoreactivity in the Central Extended Amygdala by Antidepressant Drugs". <i>Synapse</i> 31:1-4. (1999)
	Morris et al. "A Differential Neural Response in the Human Amygdala to Fearful and Happy Facial Expressions" <i>Nature</i> 383:812-815. (1996)
	Nozaki et al. "Insight Into the Neuronal Mechanism of Secretin Therapy in Autistic Children" (Abstract) In: <i>IMFAR</i> . Orlando, FL. (2002)
	Nozaki et al. "In Vitro Autoradiographic Localization of (125)I-Secretin Receptor Binding Sites in Rat Brain" <i>Biochem. Biophys. Res. Commun.</i> 292:133-137. (2002)
	Phillips. "A Specific Neural Substrate for Perceiving Facial Expressions of Disgust". <i>Nature</i> 389:495-498 (1997)
	Roberts et al. "Repeated Doses of Porcine Secretin in the Treatment of Autism: A Randomized, Placebo-Controlled Trial" <i>Pediatrics</i> 107:71. (2001)
	Rohan et al. "Match-Warped EPI Anatomic Images And The Amygdala: Imaging in Hard Places" (Abstract) In: <i>Proceedings International Society for Magnetic Resonance in Medicine</i> , p 1237. (2001)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	04843/112002
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	10/556,134
		Applicant	YURGELUN-TODD
		Filing Date	November 9, 2005
		Group	Not Yet Assigned
		IDS Filed	May 2, 2007
(37 C.F.R. § 1.98(b))			

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Rosenkranz and Grace. (2001) "Dopamine Attenuates Prefrontal Cortical Suppression of Sensory Inputs to the Basolateral Amygdala of Rats" <i>J Neurosci</i> 21:4090-4103.
	Roskoski et al. "Regulation of Tyrosine Hydroxylase Activity in Rat PC12 Cells by Neuropeptides of the Secretin Family" <i>Mol. Pharmacol.</i> 36:925-931. (1989)
	Sandler et al. "Lack of Benefit of a Single Dose of Synthetic Human Secretin in the Treatment of Autism and Pervasive Developmental Disorder" <i>N. Engl. J. Med.</i> 341:1801-1806. (1999)
	Sanders et al. "Priming of Experimental Anxiety by Repeated Subthreshold GABA Blockade in the Rat Amygdala" <i>Brain Research</i> 699:250-259. (1995)
	Repligen Corporation. "SecreFlo™ (Secretin) for Injection." (2002)
	Sheline et al. "Increased Amygdala Response to Masked Emotional Faces in Depressed Subjects Resolves With Antidepressant Treatment: An fMRI Study" <i>Biol. Psychiatry</i> 50:651-658. (2001)
	Siegle et al. "Can't Shake That Feeling: Event-Related fMRI Assessment of Sustained Amygdala Activity in Response to Emotional Information in Depressed Individuals" <i>Biol Psychiatry</i> 51:693-707. (2002)
	Tessitore et al. "Dopamine Modulates the Response of the Human Amygdala: A Study in Parkinson's Disease" <i>J. Neurosci.</i> 22:9099-9103. (2002)
	U.S. Congress, Office of Technology Assessment, <i>Biological Components of Substance Abuse and Addiction</i> , Chapter 2: Basic Concepts OTA-BP-BBS-117 (Washington, DC: U.S. Government Printing Office 9-18 (1993).
	Yung et al. "Secretin Facilitates GABA Transmission in the Cerebellum" <i>J. Neurosci.</i> 21:7063-7068. (2001)
	Yurgelun-Todd et al. "fMRI During Affect Discrimination in Bipolar Affective Disorder" <i>Bipolar Disord.</i> 2:237-248. (2000)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	